Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPACE-neo neoadjuvant apatinib + camrelizumab + SOX for locally advanced gastric/GEJ adenocarcinoma
ChiCTR2100049305Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, camrelizumab, oxaliplatin and tegafur + gimeracil + oteracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Main pathological remission rate and Safety. Started Sep 2021; status: recruiting.
02
Drugs
Rivoceranibcamrelizumaboxaliplatintegafur + gimeracil + oteracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100049305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049305.